Xenon Pharmaceuticals Inc. (XENE) Financials

XENE Assets vs Liabilities
DateAssetsLiabilities
June 30, 2026 1.3 billion 53.4 million
March 31, 2026 1.4 billion 49.0 million
Dec. 31, 2025 981.7 million 399.9 million
Sept. 30, 2025 607.8 million 48.3 million

XENE Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
June 30, 2026 -95.7 million 16.7 million
March 31, 2026 -89.0 million 16.9 million
Dec. 31, 2025 -81.8 million 14.1 million
Sept. 30, 2025 -72.0 million 13.7 million

XENE Net Income

No data available :(

XENE Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
June 30, 2026 930.7 million - 5.1 million
March 31, 2026 1.1 billion - 7.5 million
Dec. 31, 2025 548.9 million - 6.4 million
Sept. 30, 2025 462.3 million - 6.8 million

XENE Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
June 30, 2026 99.6 million
March 31, 2026 87.3 million
Dec. 31, 2025 79.3 million
Sept. 30, 2025 79.2 million

XENE Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
June 30, 2026 275000 99.2 million 23.9 million -
March 31, 2026 133000 88.5 million 23.8 million -
Dec. 31, 2025 318000 87.7 million 22.1 million -
Sept. 30, 2025 281000 77.1 million 19.3 million -

XENE Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
June 30, 2026 - -
March 31, 2026 - 587000
Dec. 31, 2025 - 611000
Sept. 30, 2025 - 77.1 million

XENE Revenue by Segment
Graph available only for paid members. Upgrade to see it.

XENE

Price: $38.02

52 week price:
35.60
72.66

Earnings Per Share: -4.63 USD

Exchange: NGM

Sector: Healthcare

Industry: Biotechnology

Country: Canada

Volume: 730900

Ebitda: -8.5 million

Market Capitalization: 5.8 billion

Links: